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http://dx.doi.org/10.1016/j.ccr.2014.01.003SUMMARYUbiquitin-like with PHD and RING finger domains 1 (UHRF1) is an essential regulator of DNAmethylation that
is highly expressed in many cancers. Here, we use transgenic zebrafish, cultured cells, and human tumors to
demonstrate that UHRF1 is an oncogene. UHRF1 overexpression in zebrafish hepatocytes destabilizes and
delocalizes Dnmt1 and causes DNA hypomethylation and Tp53-mediated senescence. Hepatocellular
carcinoma (HCC) emerges when senescence is bypassed. tp53 mutation both alleviates senescence and
accelerates tumor onset. Human HCCs recapitulate this paradigm, as UHRF1 overexpression defines a
subclass of aggressive HCCs characterized by genomic instability, TP53 mutation, and abrogation of the
TP53-mediated senescence program. We propose that UHRF1 overexpression is a mechanism underlying
DNA hypomethylation in cancer cells and that senescence is a primary means of restricting tumorigenesis
due to epigenetic disruption.INTRODUCTION
The expression of genes that encode readers and writers of the
epigenetic code are widely deregulated across cancer types
(You and Jones, 2012). This contributes to the massive gene-
expression changes and remodeling of the epigenetic land-
scape, a characteristic of many types of cancer. In particular,
loss of global DNA methylation is a hallmark of cancer cells.Significance
Global DNA hypomethylation occurs inmost types of cancer an
gene expression. UHRF1 is a key regulator of DNAmethylation,
in zebrafish without any other genetic alteration, demonstrating
hypomethylation and Tp53-mediated senescence, which serve
HighUHRF1 expression in humanHCC correlates with a poor p
of the TP53-mediated senescence program. We conclude th
hypomethylation, an epigenetic hallmark of cancer cells, and th
cence is bypassed.
196 Cancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc.DNA hypomethylation contributes to oncogenesis through
multiple mechanisms, including chromosomal instability (Eden
et al., 2003; Karpf and Matsui, 2005), derepression of imprinted
genes (Berdasco and Esteller, 2010; Jirtle, 2004; Li et al., 1993),
retrotransposon activation (Gaudet et al., 2004; Howard et al.,
2008; Jackson-Grusby et al., 2001; Sharif et al., 2007), and aber-
rant gene expression, including induction of oncogenes (Cheah
et al., 1984). Many studies have documented that expressiond can induce genomic instability andwidespread changes in
and here, we show that UHRF1 overexpression causes HCC
that it is an oncogene. High UHRF1 expression causes DNA
s to restrict transformation of UHRF1-overexpressing cells.
rognosis, genomic instability, TP53mutation, and repression
at UHRF1 is an oncogene that promotes widespread DNA
at UHRF1 overexpression drives tumorigenesis when senes-
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UHRF1 Is an Oncogene in HCCof the core factors required for maintenance DNA methylation—
i.e., DNA methyltransferase 1 (DNMT1) and ubiquitin-like with
PHD and RING finger domains 1 (UHRF1) (Babbio et al., 2012;
Jin et al., 2010; Unoki et al., 2010; Wang et al., 2012)—are signif-
icantly altered across cancer types. However, whether changes
in the expression of these key factors are sufficient to alter the
cancer cell methylome and drive carcinogenesis is unknown.
Moreover, the mechanism by which DNA methylation is lost in
cancer cells is poorly understood.
The cellular response to DNA hypomethylation varies by cell
type, physiological context, and degree of hypomethylation. In
some cells, DNA hypomethylation induces tumor-suppressive
mechanisms, including apoptosis (Anderson et al., 2009; Binisz-
kiewicz et al., 2002; Chen et al., 2007; Jackson-Grusby et al.,
2001) or senescence (Decottignies and d’Adda di Fagagna,
2011; Fairweather et al., 1987), whereas in other cells it blocks dif-
ferentiation of progenitor cells (Rai et al., 2010) or causes cancer
(Gaudet et al., 2003; Yamada et al., 2005). In part, the cellular
response to loss of DNA methylation is dictated by the genomic
region affected: hypomethylation of gene regulatory regions,
such as promoters, can derepress gene expression, whereas hy-
pomethylation of repetitive elements can reduceheterochromatin
formation and promote recombination and genomic instability.
UHRF1 plays an essential role in DNA methylation by recog-
nizing hemimethylated DNA generated during DNA replication
and then by recruiting DNMT1 to ensure faithful maintenance
of DNA-methylation patterns in daughter cells (Arita et al.,
2008; Avvakumov et al., 2008; Bostick et al., 2007; Hashimoto
et al., 2008; Liu et al., 2013; Nishiyama et al., 2013; Sharif
et al., 2007). Consequently, UHRF1 depletion results in global
DNA hypomethylation (Bostick et al., 2007; Feng et al., 2010;
Sharif et al., 2007; Tittle et al., 2011). Conversely, UHRF1 may
also limit DNA methylation by targeting DNMT1 for ubiquitin-
mediated degradation (Du et al., 2010; Qin et al., 2011) or by
delocalizing DNMT1 (Sharif et al., 2007). Thus, how UHRF1 over-
expression impacts the methylome is unclear.
We previously reported that uhrf1mutation in zebrafish blocks
liver outgrowth in embryos and regeneration in adults (Sadler
et al., 2007) and that depleting UHRF1 from cancer cells induces
apoptosis (Tien et al., 2011). Here, we tested the hypothesis that
UHRF1 overexpression would alter global DNA methylation and
promote hepatocellular carcinoma (HCC).
RESULTS
High UHRF1 Expression Causes DNA Hypomethylation
UHRF1 is required for DNA methylation, as it recruits DNMT1 to
hemimethylated DNA during DNA replication (Bostick et al.,
2007; Feng et al., 2010; Liu et al., 2013; Nishiyama et al., 2013;
Sharif et al., 2007). Paradoxically, UHRF1 also serves as an
ubiquitin ligase that targets DNMT1 for degradation (Du et al.,
2010; Qin et al., 2011). To determine howUHRF1 overexpression
impacts DNA methylation, we generated transgenic zebrafish
expressing human UHRF1 fused to GFP (hsa.UHRF-GFP)
under the hepatocyte-specific fabp10 promoter (Tg(fabp10:
hsa.UHRF1-GFP); Chu et al., 2012).
Human and zebrafish UHRF1 are 66% identical, and the ability
of human UHRF1 to rescue zebrafish embryos depleted of Uhrf1
(V.J. and K.C.S., unpublished data; Chu et al., 2012) indicatesCthey are functional orthologs. Expression is first detected in
hepatocytes on 3 days postfertilization (dpf) and by 5 dpf;
nuclear UHRF1-GFP is easily detected at variable levels in
hepatocytes (Figure S1A available online; Chu et al., 2012). We
isolated an allelic series of Tg(fabp10:hsa.UHRF1-GFP) trans-
genics expressing a range of UHRF1 levels (Figures S1A and
S1B; hereafter referred to UHRF1-GFP High,Medium and Low).
We probed genomic DNA isolated from the liver of 5 dpf larvae
from each line with an antibody specific for 5-methyl cytosine
(5MeC) to assess DNA methylation and found significant
hypomethylation only in the liver of UHRF1-GFP High larvae
(38% of controls; p = 0.007; Figures 1A and S1C). 5MeC immu-
nofluorescence showed DNA methylation to be uniformly dis-
tributed in the nuclei of hepatocytes from control larvae that
express nuclear-localized mCherry under the fabp10 promoter
(Tg(fabp10:nls-mCherry); abbreviated to nls-mCherry). Only
dim staining was detected in hepatocytes of UHRF1-GFP High
larvae (Figure 1B). Because equivalent levels of 5MeC were
detected in the liverless carcasses (Figure 1A) or cells of the fin
where the transgene is not expressed (Figure 1B), we conclude
that DNA hypomethylation was specific to the liver of UHRF1-
GFP High larvae.
We hypothesized that UHRF1-induced DNA hypomethylation
could be caused by mislocalization or destabilization of Dnmt1.
Immunofluorescence revealed uniform Dnmt1 distribution in the
nucleoplasm of nls-mCherry hepatocytes (Figure 1C), but in
UHRF1-GFP High hepatocytes, it was concentrated in nuclear
foci that contained UHRF1-GFP (Figure 1C). Interestingly, the
range of UHRF1-GFP expression within cells of the same liver re-
vealed that cells with high GFP had dim, puncate Dnmt1 staining,
but the Dnmt1 levels and distribution pattern were similar to con-
trol hepatocytes in cells with low or no GFPDnmt1 levels, and the
distribution patternwas similar to control hepatocytes in cells with
lowor noGFP (arrows,Figure1C). Thus,UHRF1expressedathigh
levels colocalizes with Dnmt1 and high UHRF1 expression redis-
tributes Dnmt1 to intranuclear structures reminiscent of senes-
cence-associated heterochromatin foci (Di Micco et al., 2011).
Endogenous Dnmt1 in the liver was below the levels detect-
able by immunoblotting (not shown), so we used a transgenic
line expressing UHRF1-GFP under the inducible hsp70l
promoter (Chu et al., 2012) to quantitatively assess the impact
of UHRF1 overexpression on Dnmt1 stability at a developmental
time when we could easily detect Dnmt1 levels by immunoblot-
ting. We optimize a heat-shock protocol that maximized UHRF1-
GFP expression in Tg(hsp70l:UHRF1-GFP) larvae (Figure 1D)
and found that UHRF1-GFP overexpression reduced Dnmt1
protein by 27% compared to non-heat-shocked transgenics
(p = 0.03; Figure 1E). Treatment with a nontoxic dose of the
proteasome inhibitor, MG132, prevented the decrease in
Dnmt1 induced by UHRF1 overexpression (p = 0.01; Figure 1E).
Neither heat shock nor MG132 significantly affected Dnmt1
protein levels in nontransgenic controls (Figure 1E). Thus, both
Dnmt1 delocalization and destabilization could account for
DNA hypomethylation caused by UHRF1 overexpression.
DNA Hypomethylation Caused by UHRF1
Overexpression Reduces Liver Size
Uhrf1 in zebrafish is required for hepatic outgrowth and liver
regeneration (Sadler et al., 2007). To determine if UHRF1ancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc. 197
Figure 1. High UHRF1 Expression Causes Global DNA Hypomethylation
(A) 5MeC levels and total DNA stained with methylene blue were measured in 5 dpf control andUHRF1-GFP High livers (n = 4) and liverless carcasses (n = 3). The
ratio of 5MeC to total DNA was averaged and normalized to controls. Student’s t test was used to determine p values.
(B) Confocal stacks of livers (top) and fins (bottom) from 5 dpf nls-mCherry and UHRF1-GFP High larvae stained with anti-5MeC. Because a hepatocyte-specific
promoter was used for transgenesis, there was no transgene expression in the fin.
(C) Dnmt1 is uniform in the hepatocyte nucleus of four dpf nls-mCherry larvae but is found in GFP-containing punctae in UHRF1-GFP High hepatocytes. Arrows
point to cells that do not express GFP and have Dnmt1 distribution pattern similar to controls.
(D) Tg(hsp70I:UHRF1-EGFP) and nontransgenic controls were heat shocked at 37C for 1 hr at 24 and 27 hpf, treated with 10 mMMG132 or DMSO at 28 hpf, and
collected at 34 hpf for immunoblotting.
(E) Dnmt1 levels normalized to tubulin were averaged from six experiments. Student’s t test was used to determine p values; n.s., not significant; error bars
represent SD.
See also Figure S1.
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UHRF1 Is an Oncogene in HCCoverexpression in hepatocytes affected hepatic outgrowth, we
assessed liver size in fish from all transgenic lines (Figures 2A–
2C and S2A). Low and medium expressing lines had no gross
changes in liver size (Figure S2A), but 74% of UHRF1-GFP
High larvae on 5 dpf had small livers (Figure 2C), with the median
area of the left liver lobe reduced by 35% compared to controls
(p < 0.001; Figures 2D and S2A), without reduction of total fish
size (Figure S2B).
Larvaewith small livers appeared sick (see 10 dpf larvae in Fig-
ure 2A), and only 20%ofUHRF1-GFPHigh fish survived to 20 dpf
(Figures S2C and 2E). Moreover, UHRF1-GFP High larvae with
the ‘‘microliver’’ phenotype on 5 dpf had significantly highermor-
tality by 10 dpf (67%) than those that started with a normal-sized
liver (7%; Figure 2E). Thus, high UHRF1 expression in hepato-
cytes causes DNA hypomethylation, microliver, and larval death.198 Cancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc.We next investigated the relationship between DNA hypo-
methylation and the microliver phenotype by asking whether
further reducing DNAmethylation could enhance this phenotype
or restoringDnmt1 could suppress it.Wepreviously reported that
exposing embryos to 50 mMof the Dnmt1 inhibitor, 5-azacytidine
(5-Aza) from 0 to 5 dpf caused a profoundly small liver and DNA
hypomethylation (Mudbhary and Sadler, 2011). By restricting
the 5-Aza exposure time to 2.5–5 dpf, we reduced DNA methyl-
ation in the liver of control larvae by 40% (Figure S1C), which
induced a moderately small liver in 16% of larvae (p = 0.0035;
Figure 2F). This same treatment of UHRF1-GFP High larvae
significantly increased the percent with small livers (p < 0.0001;
Figure 2F). Whereas this could be attributed to DNA damage
caused by 5-Aza, our finding that injecting UHRF1-GFP High
embryos with mRNA-encoding Dnmt1 modestly suppressed
Figure 2. UHRF1-Induced Hypomethylation Reduces Liver Size
(A) Individual larvae were imaged daily from 3–10 dpf.
(B) Five dpf UHRF1-GFP High larvae display a range of liver sizes scored as ‘‘normal’’ or ‘‘small’’.
(C) Three clutches were scored according to criteria in (B); n, number of larvae. Fisher’s exact test was used to determine p value.
(D) The area of the left liver lobe wasmeasured in 5 dpf fish from two clutches. Boxes represent 75th and 25th percentile, horizontal line is themedian, andwhiskers
mark lowest and highest values. Student’s t test was used to determine p value.
(E) UHRF1-GFP High larvae were sorted by liver size on 5 dpf and tracked daily for survival to 20 dpf. Data are pooled from three clutches.
(F) UHRF1-GFP High and control larvae were treated with 50 mM 5-Aza from 2.5–5 dpf and scored for liver size in six clutches. Fisher’s exact test was used to
determine p values.
(G)UHRF1-GFPHigh embryos were injected with mRNA encoding dnmt1 orMpi before 1 hpf. The percent of fish with a normal liver size was scored at 5 dpf in six
clutches.
See also Figure S2.
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UHRF1 Is an Oncogene in HCCthe percent of fish with a small liver (Figure 2G) and increased the
average size of the left liver lobe by 10%–15% (Figure S2D) sug-
gests that hypomethylation, at least in part, contributes to the
small-liver phenotype of UHRF1-GFP High larvae.
UHRF1 Overexpression Triggers Tp53-Mediated
Senescence
DNA hypomethylation can induce apoptosis, but we found no
TUNEL-positive cells on 5 dpf in UHRF1-GFP High livers (Fig-
ure S3A). However, senescence-associated b-galactosidase
(SA-b-gal) staining was detected throughout the liver of most
UHRF1-GFP High 5 dpf larvae (n = 93; Figures 3A and 3B), but
not other transgenic lines (Figure S3B). Additionally, the DNACin control hepatocytes was evenly distributed throughout the
uniformly sized nuclei compared to the large nuclei where DNA
resembled senescence-associated heterochromatic foci (inset,
Figure 3C). Strikingly, the largest hepatocyte nuclei also had
the brightest GFP (Figure 3C), suggesting the effect of UHRF1
overexpression cell autonomously affected nuclear morphology.
Senescent cells do not divide, and we found significantly less
bromodeoxyuridine (BrdU) incorporation in the liver of 5 dpf
UHRF1-GFP High larvae compared to controls (p < 0.0001; Fig-
ure 3D). Interestingly, in nls-mCherry larvae, most BrdU incorpo-
ration was detected in hepatocytes that express nls-mCherry,
but the only BrdU-positive cells in UHRF1-GFP High larvae
were negative for GFP (see inset in Figure 3D). RNA sequencingancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc. 199
Figure 3. UHRF1 Overexpression in Hepa-
tocytes Induces Tp53-Mediated Senes-
cence
(A) Intense senescence-associated b-galactosi-
dase (SA-b-gal) staining was detected in the liver
(outlined) of 5 dpf UHRF1-GFP High larvae
compared to light or no staining in controls.
(B) Five dpf fish from five clutches were scored
for hepatic SA-b-gal staining. ***p < 0.0001 by
Fisher’s exact test.
(C) Nuclear size was measured in hepatocytes of a
single control or UHRF1-GFP High 5 dpf liver, and
cells were stratified according to GFP expression.
Inset shows confocal stack of the DNA organized
into foci. **p < 0.001 and ***p < 0.0001, compared
to nuclear size in nls-mCherry larvae.
(D) BrdU-positive cells and the total number of
transgene-expressing hepatocytes in nls-mCherry
andUHRF1-GFPHigh larvae (bottom) 5 dpf larvae.
A Fisher’s exact test was used to calculate p value.
In nls-mCherry larvae, most BrdU-positive cells
also express the transgene, whereas the BrdU-
positive cells in UHRF1-GFP High livers did not
express GFP (white arrows in magnified regions,
which are marked by the white box).
(E) Heatmap of log2 values from RNA-seq shows
cell-cycle regulators are down and Tp53 target
genes (marked by *) are up in UHRF1-GFP High 5
dpf livers.
(F) tp53 and cdkn1a mRNA expression were
induced on 5 dpf and downregulated on 20 dpf in
UHRF1-GFP High livers. *p = 0.05; ***p = 0.001
calculated by one sample Student’s t test. Error
bars represent SD.
(G) 5-Aza induces Tp53 expression in primary
mouse hepatocytes. Student’s t test was used to
determine p value with SD indicated by the error
bars across three replicates.
(H–K) tp53+/ in UHRF1-GFP High larvae signifi-
cantly reduced SA-b-gal staining in the liver (two
clutches) (H), and increased the percent of larvae
with normal liver size (I), the area of the left liver
lobe (J), and survival at 5 dpf (K). p values were
calculated with a Fisher’s test with Freeman-
Halton extension (H), Fisher’s exact test (I), and
Student’s t test. Boxes represent 75th and 25th
percentile, horizontal line is the median, and
whiskers mark lowest and highest values (J).
See also Figure S3.
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UHRF1 Is an Oncogene in HCC(RNA-seq) analysis of liver samples from 5 dpf revealed down-
regulation of some proproliferative genes (ccnd1 and myc)
(Figure 3E), lending further support to the conclusion that senes-
cence is the primary response to high UHRF overexpression in
hepatocytes during hepatic outgrowth.200 Cancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc.TP53 is a key mediator of senescence
caused by DNA damage and oncogenic
stress (Di Micco et al., 2011; McDuff
and Turner, 2011; Ventura et al., 2007;
Xue et al., 2007). RNA-seq (Figure 3E)
and quantitative PCR (qPCR) analysis
(Figure 3F) show that tp53 and its target
genes, especially cdkn1a, are signifi-cantly induced in the liver of 5 dpf UHRF1-GFP High larvae but
then return to baseline by 20 dpf (Figure 3F). 5-Aza treatment
of primary mouse hepatocytes induced Tp53 expression (Fig-
ure 3G), similar to the effects of 5-Aza treatment or Dnmt1 deple-
tion in other mammalian cell types (Jackson-Grusby et al., 2001;
Cancer Cell
UHRF1 Is an Oncogene in HCCKarpf et al., 2001) and in zebrafish embryos (V.J. and K.C.S., un-
published data; not shown). However, because significant alter-
ation in methylation of the tp53 promoter was not detected in
these models (not shown), we hypothesize that DNAmethylation
does not directly regulate Tp53 expression. Instead, DNA hypo-
methylation may induce tp53 by an indirect mechanism, such as
increased DNA damage or genomic instability.
A direct role for Tp53 in the phenotypes induced by UHRF1
overexpression was demonstrated by removing one copy of
tp53. This reduced the incidence and intensity of SA-b-gal
staining in the liver (Figure 3H), increased liver size (Figures 3I
and 3J), and reduced mortality (Figure 3K) of UHRF1-GFP High
fish. We thus propose a model whereby high UHRF1 causes
DNA hypomethylation, induces Tp53-mediated senescence,
which prevents expansion of the hepatic bud, resulting in hepatic
insufficiency and larval death.
UHRF1 Overexpression Induces Liver Cancer in
Zebrafish
To determine if UHRF1 overexpression was sufficient to cause
HCC, 281 control and UHRF1-GFP transgenics were collected
between 5 and 300 dpf, serial sectioned, and analyzed for atyp-
ical cells, dysplastic foci, and HCC using histological criteria
devised by two expert pathologists (R.T.B. and M.I.F.), which
included disrupted tissue architecture, cell size, shape, nuclear
structure, and the presence of mitotic figures (Figures S4A and
S4B). Evidence of increased hepatocyte proliferation was de-
tected in all UHRF1-overexpressing lines on 20 and 40 dpf (Fig-
ure S4C), but this was insufficient to cause HCC, asUHRF1-GFP
Low fish were tumor free at all time points (Table 1). In contrast,
UHRF1-GFP High fish developed atypical hepatocytes as early
as 5 dpf, with an 8% incidence of dysplastic foci and 46%
incidence of HCC by 15 dpf. On 20 dpf, 76% of fish had HCC
(Figures 4A and 4B; Table 1). UHRF1-GFP Medium fish also
developed atypical hepatocytes and dysplastic foci at young
ages, and one large HCC was detected in a 60 dpf fish (Table 1).
In a classical transformation assay using NIH 3T3 cells, UHRF1
cooperatedwith RAS to promote growth on soft agar (Figure 4C).
These conclusively demonstrate that UHRF1 is an oncogene.
We found that UHRF1-GFP High larvae older than 8 dpf had a
lower incidence and intensity of hepatic SA-b-gal staining
(Figure 4D). Interestingly, in many of these fish, intense staining
was distributed in a punctate pattern. By 20 dpf, 75% of fish
had either punctate or no staining (Figure 4D), which is a striking
correlation with the 70% incidence of HCC at this time point. This
wasmirrored by increased proliferation of liver cells, detected by
increased BrdU incorporation in UHRF1-GFP High livers (22%
versus 4% in controls) at 11 dpf (p < 0.001; Figure 4E), and higher
PCNA staining on 20 and 40 dpf in all lines (Figure S4C). Loss of
senescence was not attributed to re-establishment of DNA
methylation or transgene silencing, as reduced 5MeC staining
persisted in tumor cells (Figure S4D) and transgene expression
was detectable in all 20 dpf fish (Figures S4E and S4F), albeit
reduced from levels detected in 5 dpf livers.
We asked whether Tp53 epistatically interacted with UHRF1
overexpression to contribute to HCC by removing one copy of
tp53 (Berghmans et al., 2005). The liver appeared normal in 13
tp53+/ fish without transgene expression (not shown), but in
UHRF1-GFP High fish, tumor incidence on 15 dpf increasedCfrom 50% in wild-type (WT) to 87% in tp53+/ fish (Figure 4B).
Interestingly, in a single UHRF1-GFP High);p53+/, 15 dpf fish,
we found a tumor with immature cells resembling a cholangio-
carcinoma. Thus, tp53 functions to suppress tumor formation
and may alter the spectrum of tumors caused by UHRF1
overexpression.
UHRF1 Is Upregulated in Human HCC
We next investigated the relevance of UHRF1 expression in
human HCC. We assessed UHRF1 expression by qPCR in 16
normal liver samples and in two cohorts of patients with
dysplastic nodules or HCC: the first cohort of 58 patients had
hepatitis C infection (HCV) (Figure 5A; Wurmbach et al., 2007),
and the second cohort of 69 patients had hepatitis B virus,
alcohol, and other etiologies (Figure S5A; Villanueva et al.,
2008). Additional publically available transcriptome data sets
from three other cohorts of HCCs (Figure S5B) and from lung,
gastric, colorectal, and breast cancer (Figure S5C) were also
analyzed. All showed elevated UHRF1 in tumors, with expres-
sion elevated >2-fold compared to controls in 17/18 dysplastic
foci and 104/109 HCCs (Figures 5A and S5A). An average of
20- and 46-fold overexpression of UHRF1 was detected in
advanced and very advanced HCCs. UHRF1 protein was barely
detectable in five normal liver samples but highly expressed in
38/52 (73%) of the tumors analyzed for UHRF1 mRNA in Fig-
ure 5A (p < 0.003; Figure 5B). Thus, UHRF1 is overexpressed
in HCCs of diverse etiologies as well as in other tumor types,
and high UHRF1 expression is significantly associated with the
most advanced tumors.
Targeting UHRF1 in liver cancer cells (HepG2) using small
interfering RNA (siRNA) induced PARP cleavage (Figure 5C)
and other markers of apoptosis (not shown), similar to results
obtained using another HCC cell line (Hep3B; not shown) and
colon cancer cells (Tien et al., 2011). Thus, blocking UHRF1 in
cancers with high UHRF1 expression could be an effective
means to induce tumor cell death.
Of the 109 HCCs analyzed forUHRF1 expression by qPCR, 71
had multiple clinical and genomics parameters available (Chiang
et al., 2008). These were rank-ordered based on UHRF1 expres-
sion determined by qPCR (Figure 6A). Tumors with expression
above and equal to or below the median log2-fold change value
of 3.64 were designated as ‘‘high’’ (n = 35) and ‘‘low’’ (n = 36),
respectively (Figure 6A). High-UHRF1-expressing tumors were
associated with signs of poor clinical outcome: 80% had
microvascular invasion (Figure 5D) and significantly higher
alpha-fetoprotein (AFP) levels (Figure 5E), although AFP levels
alone did not cooperate with UHRF1 to predict survival (data
not shown). Importantly, high UHRF1 expression significantly
correlated with early (<2 years; Figure 5F), but not late (Fig-
ure 5G), tumor recurrence and was inversely correlated with
survival (Figure 5H). This suggests that high UHRF1 expression
predicted recurrence of the primary tumor, causing decreased
survival (Villanueva et al., 2011). Molecular signatures of aggres-
sive HCC tumors compiled from several previous studies (Table
S1) were concordantly and significantly enriched in high-UHRF1-
expressing tumors (Figure 6A). Moreover, high-UHRF1-express-
ing tumors were distinguished by induction of pathways that
drive the cell cycle, DNA replication, and repair (Figure S6A;
Tables S2 and S3). UHRF1 overexpression also significantlyancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc. 201
Table 1. HCC Onset and Incidence in Tg(fabp10:nls-mCherry) and Tg(fabp10:UHRF1-GFP) Zebrafish
Transgene dpf 5 10 15 20 25 30 40 50 60 90 180 300 Total n = 281 CI
nls-mCherry normal 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 65 100%
atypical cells 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
dysplastic foci 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
tumor 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
n = 8 8 8 11 nd nd 5 5 5 5 5 5 65
UHRF1-GFP Low normal 100% 100% 100% 100% 100% 100% 100% 100% 60 100%
atypical cells 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
dysplastic foci 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
tumor 0% 0% 0% 0% 0% 0% 0% 0% 0 0%
n = 7 9 10 12 nd nd 4 nd nd 6 6 6 60
UHRF1-GFP Medium normal 90% (9) 100% (11) 50% (3) 28% (4) 66% (4) 80% (4) 50% (4) 50% (5) 81% (13) 57 66%
atypical cells 10% (1) 0% 50% (3) 57% (8) 33% (2) 20% (1) 50% (4) 20% (2) 44% (7) 28 32%
dysplastic foci 0% 0% 0% 7% (1) 0% 0% 25% (2) 30% (3) 0% 6 7%
tumor 0% 0% 0% 0% 0% 0% 0% 0% 6% (1) 1 1%
n = 10 11 6 14 6 5 8 10 16 86
UHRF1-GFP High normal 0% 0% 7% (1) 0% 0% 1 2%
atypical cells 100% (13) 100% (7) 46% (6) 17% (3) 75% (3) 36 61%
dysplastic foci 0% 0% 8% (1) 12% (2) 25% (1) 4 7%
tumor 0% 0% 46% (6) 76% (13) 0% 18 30%
n = 13 7 13 17 4 54
UHRF1-GFP High/ p53+/ normal 0% 0 0%
atypical cells 13% (2) 2 13%
dysplastic foci 0% 0 0%
tumor 88% (14) 14 88%
n = 16 16
The incidence (percent) and absolute number of fish (parentheses) with cancer-relevant histological phenotypes were scored in a total of 281 fish from four transgenic lines. The total n for each time
point is indicated. Some fish were diagnosed with more than one lesion. nd, not done; CI, cumulative incidence.
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Figure 4. UHRF1 Is an Oncogene
(A) Atypical cells, dysplastic foci (outlined), and
HCC are apparent in hematoxylin and eosin-
stainedUHRF1-GFP High livers. BD, bile duct; MF,
mitotic figure.
(B) Incidence of normal and atypical hepatocytes,
dysplastic foci, and cancer in the liver of UHRF1-
GFP High fish on WT or tp53+/ background.
(C) NIH 3T3 cell growth in soft agar is enhanced
when UHRF1 overexpression is combined with
RAS (n = 3). The p value was calculated by Stu-
dent’s t test, and error bars represent the SD.
(D) Hepatic SA-b-gal-staining patterns in UHRF1-
GFP High larvae change as fish age. Images of 8
dpf larvae illustrate the SA-b-gal-staining patterns
that were scored in the time course shown in the
graph. A significant increase in the number of
UHRF1-GFP High fish with intense or punctate
SA-b-gal compared to controls at all time points
(p < 0.01 by Fisher’s exact test) except at 4 dpf;
n.s., not significant.
(E) BrdU incorporation in the liver on 11 dpf is five
times higher in UHRF1-GFP High fish than in
controls. Total number of cells counted is indicated
with n = number of clutches assessed. Fisher’s
exact test was used to calculate p value. See also
Figure S4.
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UHRF1 Is an Oncogene in HCCcorrelated with advanced-stage prostate cancer, but not lung
or colon (Figures S5D–S5G).
High UHRF1 Expression Delineates a Subclass of HCCs
that Have Downregulated TP53-Mediated Senescence
Our zebrafish studies demonstrated that bypass of Tp53-
induced senescence is required for UHRF1 to act as an
oncogene. Our analysis of human HCCs indicates that a similar
paradigm occurs in these samples. First, inactivating mutations
in TP53 significantly correlated with high UHRF1 expression
(Figure 6A). Second, many of the core enriched genes high-
UHRF1-expressing tumors are regulated by TP53 in senescent
fibroblasts (Table S4; Tang et al., 2007), and high-UHRF1-
expressing tumors downregulated the gene expression signa-
ture associated with TP53-induced senescence in fibroblasts
(Table S5; Figure S6B; Tang et al., 2007) and in hepatic stellate
cells (Table S6; Figure S6C; Lujambio et al., 2013). Fourth, signif-
icant correlation between UHRF1 overexpression, TP53 muta-
tion, and genome integrity in human HCCs indicates that these
pathways act together, where high UHRF1 expression (FiguresCancer Cell 25, 196–209,6B and 6C) and TP53mutation (Figure 6D)
are independently correlated with chro-
mosomal loss, but tumors that have
both features display even more chro-
mosomal loss (Figure 6D). Finally,
UHRF1 expression was significantly
higher in tumors with TP53 mutation
(Figure 6E). UHRF1 overexpression did
not correlate with copy-number variation
at theUHRF1 locus (Figure S6D) suggest-
ing that a different mechanism drives
UHRF1 overexpression.Genome-wide DNA hypomethylation is found in most HCCs
(Calvisi et al., 2007), and this rendered it difficult to correlate
methylome changes with UHRF1 expression. However,
DNMT1 expression was directly correlated with UHRF1 expres-
sion in HCC samples (Figure 6F). This may be a consequence
of the high proliferation rate in these tumors or an induction
of the methylation machinery to compensate for hypomethy-
lation. Together, these data indicate that high UHRF1 expression
in HCC defines a subset of aggressive tumors that have in-
activated the TP53-induced senescence program, suggesting
that, in humans, as observed in zebrafish, TP53 acts as a tumor
suppressor to restrict the oncogenic potential of UHRF1-over-
expressing cells.
DISCUSSION
We show that UHRF1 overexpression is sufficient to cause two
oncogene-associated phenotypes: senescence and cancer.
This defines UHRF1 as an epigenetic regulator that causes
cancer upon overexpression, and it is thus an oncogene. WeFebruary 10, 2014 ª2014 Elsevier Inc. 203
Figure 5. UHRF1 mRNA and Protein Are Overexpressed in HCC
(A) UHRF1 detected by qRT-PCR in 18 preneoplastic lesions and 40 HCCs from hepatitis C virus (HCV)-infected patients compared to expression in nine normal
livers. Horizontal line indicates median.
(B) Immunohistochemistry for UHRF1 protein (brown) was evaluated in 52 of the same HCCs examined in (A) plus five normal liver samples. Fisher’s exact test
was used to calculate p value. Seventy-one of the HCV-associated HCCs analyzed by qPCR were grouped into high (n = 35) and low (n = 36) UHRF1-expressing
tumors based on the median log2-fold change of 3.64.
(C) HepG2 cells transfected with control siRNA (GL2) or two different siRNAs targeting UHRF1 described in Tien et al. (2011) were blotted for UHRF1 and cleaved
and total PARP (arrow indicates full length; * indicates cleaved protein).
(D–H) Vascular invasion (33 high and 34 low tumors; fourmissing values) (D), serumAFP (29UHRF1-high and 29 low tumors; 13missing values) (E), early (<2 years)
(F) and late (>2 years; 32 UHRF1-high and 35 low tumors; four missing values) (G) tumor recurrence, and overall survival after surgery (32 high and 35 low tumors;
four missing values) (H) were stratified according to UHRF1 expression. Continuous and categorical variables were assessed by Wilcoxon rank-sum test and
Fisher’s exact test, respectively. Clinical outcome difference was evaluated by log rank test. In box and whisker plots, boxes represent the 75th and 25th
percentiles, the whiskers represent the most extreme data points within interquartile range 3 1.5, and the horizontal bar represents the median.
See also Figure S5.
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UHRF1 Is an Oncogene in HCChypothesize that UHRF1 overexpression is one mechanism by
which cancer genomes can become hypomethylated, either
via UHRF1-mediated Dnmt1 ubiquitination and degradation
(Du et al., 2010; Qin et al., 2011) or by redistribution and/or
sequestration of Dnmt1 away from DNA. Excess UHRF1 might204 Cancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc.also sequester the DNMT1-deubiquitinating enzyme, USP7
(Qin et al., 2011), to further promote DNMT1 ubiquitination and
degradation.
The precise mechanism by which DNA hypomethylation
causes cancer remains elusive. Both apoptosis and senescence
Cancer Cell
UHRF1 Is an Oncogene in HCCserve to limit the propagation of cells with aberrant DNA methyl-
ation (Decottignies and d’Adda di Fagagna, 2011; Fairweather
et al., 1987); however, once epigenetically altered cells escape
these tumor-suppressive mechanisms, they likely accumulate
genetic lesions that predispose to cancer. Indeed, chromosomal
instability and mitotic catastrophe occur following DNMT1
depletion (Chen et al., 2007; Karpf and Matsui, 2005; Weber
and Schu¨beler, 2007), and transposons, which are heavily meth-
ylated in normal cells, could become activated and cause
genomic instability uponUHRF1-induced DNA hypomethylation.
Additionally, hypomethylated DNA is more likely to assume an
open chromatin conformation, which may promote oncogene
expression, although this possibility has not been fully evaluated.
Whereas the oncogenic role of UHRF1 could also be mediated
by the impact of UHRF1 on other epigenetic marks or on DNA
replication (Taylor et al., 2013), our data combined with findings
from others (Eden et al., 2003; Gaudet et al., 2003) suggest that
DNA hypomethylation is a likely mechanism driving UHRF1-
mediated transformation.
Our working model (Figure 7) proposes that UHRF1 over-
expression causes DNA hypomethylation by reducing Dnmt1
levels and its access to hemimethylated DNA. Tp53 is then
induced in response to either genomic instability or some other
mechanism, causing hepatocyte senescence, which prevents
hepatic expansion and results in larval death from hepatic insuf-
ficiency. We propose that Tp53 inactivation and senescence
bypass by an as of yet unknownmechanism and allow for unhin-
dered cell proliferation and malignant transformation. How this
tumor-suppressive mechanism is overcome remains a central,
unanswered question in cancer biology.
Studies in a mouse liver cancer model show that Tp53 re-
activation causes senescence, and these cells are then cleared
by the immune system (Xue et al., 2007) and the liver is then
repopulated with senescence-resistant tumor-forming cells.
Our finding that senescence decreases and BrdU incorporation
increases inUHRF1-GFP High livers over time suggests a similar
process at play. Moreover, BrdU incorporation in primarily GFP-
negative cells suggests the expansion of either immune cells or
immature hepatic progenitors in response to senescent hepa-
tocytes. The finding of a cholangiocarcinoma in a UHRF1-GFP
High/p53+/ fish may indicate a bipotential progenitor cell
as the tumor-forming cell in this model. Additionally, our data
indicate that there is a threshold effect of UHRF1 expression,
in which the highest expressing cells undergo senescence
and neighboring hepatocytes expressing UHRF1-GFP at levels
below those detectable via microscopy undergo unhindered
expansion.
HCC is the third cause of cancer-related deaths globally
(Llovet et al., 2003), yet curative therapies are limited, with
sorafenib as the only systemic therapy available for advanced
cases (Llovet et al., 2008). Thus, there is an urgent and unmet
need for novel therapies. HCC, like other cancers, is character-
ized by global DNA hypomethylation (Calvisi et al., 2007; Pog-
ribny and Rusyn, 2014; Tischoff and Tannapfe, 2008), and high
UHRF1 expression could be the cause. Our finding that
UHRF1 depletion in HCC and other types of cancer cells causes
apoptosis (Tien et al., 2011) presents UHRF1 as an attractive
target for inducing cancer cell death induced by massive epi-
genetic changes incompatible with cell survival or by resettingCthe cancer cell methylome to reinstate the expression of genes
that block cell proliferation.EXPERIMENTAL PROCEDURES
Zebrafish Maintenance and Generation of Transgenics
Zebrafish were maintained on a 14:10 hr light:dark cycle at 28C. mRNA-
encoding zebrafish Dnmt1 (Rai et al., 2006) or mannose phosphate isomerase
(Mpi) (Chu et al., 2013) as a control was injected into embryos just after
fertilization.
Tg(fabp10:nls-mCherry) fish expressing nls-mCherry exclusively in hepato-
cytes were generated using Gateway cloning (Invitrogen) to produce vectors
with tol2 transposon sites (Kwan et al., 2007). Tg(hsp70l:hsa.UHRF1-GFP)
and Tg(fabp10:hsa.UHRF1-GFP) were described in Chu et al. (2012). The
high, medium, and low expressing alleles are listed at http://www.ZFIN.org
with superscripts mss1a, mss1b, and mss1c, respectively. Transgenics were
outcrossed to Tab14 (WT) or tp53/ fish (Berghmans et al., 2005).
Tg(hsp70l:UHRF1-GFP) embryos were heat shocked at 37C for 1 hr at 24
and 27 hr postfertilization (hpf). At 28 hpf, embryos were sorted visually for
GFP expression and incubated with either 10 mM MG132 or DMSO and
collected for immunoblotting at 34 hpf. 5-Aza (50 mM) was added to larvae
from 2.5 to 5 dpf. The Mount Sinai Institutional Animal Care and Use Commit-
tee approved all protocols. Nomenclature guidelines for the species under dis-
cussion were followed, and when no species are specified, human nomencla-
ture was used.Gene-Expression Analysis
RNA was isolated from a pool of at least ten livers from 5 dpf fish and from one
to five livers from 20 dpf fish using the RNeasy mini-kit (QIAGEN). cDNA was
prepared by polyA priming using qScript SuperMix (Quanta). Quantitative
RT-PCR (qRT-PCR) analysis was performed in the Light Cycler 480 (Roche)
using gene-specific primers (see Supplemental Information) and PerfeCTa
SYBRGreen FastMix (Quanta). Ct values from triplicate reactions were
averaged and 2Ct(target)/2Ct(reference) was used to calculate expression, with
rpp0 and cyclophilin A used as reference genes of zebrafish and mouse
samples, respectively.
RNA-seq analysis was carried out on RNA from pools of 50 livers dissected
from two clutches of 5 dpf UHRF1-GFP High and nls-mCherry larvae,
described in Supplemental Information.Histology
Fish younger than 20 dpf were fixed overnight at 4C in 4% paraformaldehyde
(PFA), and older fish were fixed for 2–5 days at room temperature in Bouin’s
fixative. Four micromolar serial sections of paraffin-embedded fish were
stained with hematoxylin and eosin as described (Imrie and Sadler, 2010)
and imaged on an Olympus BX41 clinical microscope equipped with a Nikon
DS-Ri1 digital camera. Histological criteria used for scoring tumors are
described in Figures S4A and S4B.Immunoblotting
Lysates prepared from 15 embryos dissolved in 150 ml protein lysis buffer
were homogenized by sonication. One embryo equivalent was loaded per
lane of an 8% or 12% SDS gel, transferred to nitrocellulose, and blotted.
HepG2 cell lysates were prepared as described (Tien et al., 2011).Antibodies
Antibodies recognizing DNMT1 (1:1,000 for blotting; 1:10 for immuno-
fluorescence; Santa Cruz Biotechnology), UHRF1 (immunoblotting:
1:1,000; BD Biosciences; immunohistochemistry: 1:50; ab57083; Abcam),
tubulin (1:5,000; Developmental Studies Hybridoma Bank), p89 PARP and
total PARP (1:1,000; Cell Signaling Technology), B-actin (1:2,000; Sigma),
5MeC (1:500; Eurogentec), BrdU (1:200; BD Bioscences), and anti-rabbit
or mouse conjugated to Alexa 555 or Alexa 488 (1:100; Invitrogen) were
diluted in 10% fetal bovine serum (FBS) or 2% BSA in 1% Triton in PBS
(PBST).ancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc. 205
Figure 6. High UHRF1 Expression Defines a Subclass of Tumors with Inactivated tp53, Repression of Senescence, and Chromosomal Insta-
bility
(A) The 71 human HCC tumors analyzed in Figures 5C–5G were rank-ordered according to UHRF1 expression by qPCR and classified as high (<median, red; n =
35) or low (Rmedian, blue; n = 36). The presences of aggressive human HCC gene signatures from published studies and of TP53-inactivating mutations are
indicated by red and black boxes, respectively. TP53-mediated senescence gene signatures (Lujambio et al., 2013; Tang et al., 2007) are displayed as a range
from repressed (blue) to activated (red).
(B) Genome-wide profile of DNA copy number variation was obtained from Gene Expression Omnibus gene set GSE9829.
(C) Proportion of genes with DNA copy number loss and gain in tumors according to UHRF1 expression.
(legend continued on next page)
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Figure 7. Model of the Relationship between UHRF1 Overexpres-
sion, DNA Hypomethylation, Tp53-Mediated Senescence, Cancer,
and Survival
Factors investigated in this study are in solid black boxes with black lines
indicating the correlations demonstrated in this work and gray lines indicating
relationships that are speculative. Senescence reduces liver size and function
and reduces larval survival, whereas cancer occurs when senescence is
bypassed and also reduces survival.
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Larvae fixed in 4% PFA were washed in PBST and stained using the Senes-
cence b-Galactosidase Staining Kit (Cell Signal) or stained with CY3-strepta-
vadin (1:300; Sigma) as described (Sadler et al., 2005). The left liver lobe
area was measured using ImageJ.
Immunofluorescence was carried out on whole fish or on livers dissected
from fixed larvae. BrdU was added to larvae water (10 mM) for 4–6 hr followed
by immediate fixation, dehydration in methanol, rehydration to PBST, and
permeabilization with 10 mg/ml Proteinase K. DNA was denatured in 1 or 2 N
HCl, renatured, and blocked in 10% FBS or 1% BSA in PBST prior to immuno-
fluorescence. DNA was stained with Hoechst 33342 (Sigma). A Leica SP5 DM
confocal microscope was used for imaging.
Slot Blots
Genomic DNA was denatured in 0.4 M NaOH at 95C for 10 min and neutral-
ized in an equal volume of cold 2 M ammonium acetate, and 100 ng DNA
was blotted in duplicate onto nitrocellulose membrane using a slot blot
apparatus, washed in 23 saline sodium citrate, and vacuum baked at 80C
for 2 hr. Half was stained with 0.2% methylene blue in 0.3 M NaOAc and the
other with anti-5MeC followed by horseradish peroxidase-conjugated anti-
mouse (1:2,000) and visualized by Chemilumiescence (Roche). Image J was
used to quantify 5MeC and methylene blue intensity, and 5MeC levels were
determined by normalizing to total DNA.
Cell Culture
Primary mouse hepatocytes were isolated and plated in triplicate at 50%
confluency and then treated with 5 mm 5-Aza or DMSO for 24 hr, and RNA
was isolated.(D) Proportion of genes with DNA copy number loss according to UHRF1 expres
(E) UHRF1 expression is significantly higher in tumors with TP53 mutations.
(F) DNMT1 expression by microarray analysis is significantly correlated with UH
represent the 75th and 25th percentiles, the whiskers represent the most extreme
the median.
See also Figure S6 and Tables S1, S2, S3, S4, S5, and S6.
CNIH 3T3 cells were transfected in triplicate with pCDNA3.1 lacking an insert
(control) or containing human RAS, UHRF1, or both and were retransfected
24 hr later. Forty-eight hours after the second transfection, 700 mg /ml
neomycin was added for 7 days. Ten thousand cells per condition were plated
on 0.3% soft agar layered on top of 0.6% soft agar. Media was changed every
third day for 2 weeks, plates were stained with 0.005% crystal violet, and
colony number was counted.
HepG2 cells cultured in DMEM supplemented with 10% (v/v) FBS and 5%
(w/v) penicillin-streptomycin were transfected twice, 24 hr apart, with 20 nM
siRNA-targeting firefly luciferase (GL2; Dharmacon) or UHRF1-targeting si-A
and si-B using RNAiMAX (Invitrogen) as described (Tien et al., 2011).
Human Tissue Samples
Pathologically staged human tumors, dysplastic foci, and normal liver samples
were obtained from the HCC Genomic Consortium (Mount Sinai Hospital,
Instituto Nazionale dei Tumori, and Hospital Clinic). The study was approved
by the institutional review board of each institution, and informed consent was
obtained from all participants. TaqMan probes were used to analyze UHRF1
expression by qPCR as described (Villanueva et al., 2008). Samples were
grouped into a training set (nine normal liver, 18 low- and high-grade dysplastic
nodules, and 40 pathologically staged HCCs; Llovet et al., 2006; Wurmbach
et al., 2007) and a validation set (seven normal liver and 69 HCC; Villanueva
et al., 2008). Integrative genomic and clinical data analysis was performed on
71 of the hepatitis-C-related, surgically treated HCC patients (National Center
for Biotechnology Information [NCBI] Gene Expression Omnibus accession
numbers GSE9829 and GSE44970). The liver pathologist, S.T., scored UHRF1
staining of 52 paraffin-embedded tumors from the training set.
Bioinformatics and Statistical Analysis
Seventy-onepatientswithHCCwere groupedbasedon themedian expression
level of UHRF1 in the tumors determined by qPCR (UHRF1-high: n = 35 or low:
n = 36). Presence of aggressive human HCC gene signatures (Table S1) were
evaluated in the transcriptome data set using nearest-template prediction
method (Hoshida, 2010) implemented by the GenePattern genomic analysis
tool kit (http://www.broadinstitute.org/genepattern) based on prediction confi-
dencep<0.05. The senescence-related TP53 target geneswere obtained from
Molecular Signature Database (MSigDB; http://www.broadinstitute.org/
msigdb; TANG_SENESCENCE_TP53_TARGETS_UP and _DN; Tang et al.,
2007) and from NCBI Gene Expression Omnibus (GSE39469; Lujambio et al.,
2013). Mouse genes from normalized microarray data were converted to
human orthologs based on a mapping table (http://www.informatics.jax.org).
Differentially expressed genes between senescent and proliferative cells
were identified by using Bayesian t test implemented in Cyber-T software
(http://molgen51.biol.rug.nl/cybert) at the significance threshold of posterior
probability of differential expression >0.998 after excluding less variable genes
with coefficient of variation %0.1 across the samples. Expression pattern of
each signaturewas assessed by nearest-template prediction algorithm. Signif-
icance of induction or suppression of each signature was quantitatively
measured by nominal p value of cosine distance. Pearson correlation test
determined the significance between induction and suppression of gene signa-
tureswithUHRF1mRNAexpression level asmeasuredbyqPCR.Statistical dif-
ference betweengroupswas assessedbyWilcoxon rank-sum test andFisher’s
exact test for continuous and categorical variables, respectively. Bonferroni
correction for multiple hypothesis testing was applied when appropriate.
Survival analysis was performed by using Kaplan-Meier estimator and log
rank test. All analyses were performed using R statistical package (http://
www.r-project.org) and GenePattern genomic analysis tool kit (http://www.
broadinstitute.org/genepattern). Gene expression levels and liver size were
compared using Student’s t or Mann Whitney U tests.sion and TP53 mutation status.
RF1 expression assessed by qPCR in HCCs. In box and whisker plots, boxes
data points within interquartile range 3 1.5, and the horizontal bar represents
ancer Cell 25, 196–209, February 10, 2014 ª2014 Elsevier Inc. 207
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